Co-Founder and Scientific Advisor
David B. Sykes, MD, PhD, is a scientific founder of Clear Creek Bio, inspired by a love of science and medicine. He spent his college summers in the lab working on yeast genetics. malignant melanoma, and hepatitis C. With the goal of becoming a 'triple-threat' (scientist, physician, educator), he entered the medical scientist training program (MSTP) at the University of California, San Diego where he worked on models of acute myeloid leukemia and systems of conditional differentiation. David completed his residency training at the Massachusetts General Hospital (MGH) and fellowship training in the combined MGH / Dana-Farber Cancer Institute (DFCI) program.
David is currently a hematologist-oncologist at the MGH. He sees outpatients in hematology clinic, consults on hospitalized patients four weeks out of every year, and spends the rest of his time in the laboratory. He recognizes that patients themselves are the strongest motivating factor for research. He led the team that discovered that inhibition of the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) could drive differentiation in acute myeloid leukemia. This was an unexpected discovery that led to a reevaluation of the drug brequinar which had been previously studied in the treatment of patients with solid tumor malignancies.
David recognizes the biological complexity that each patient presents. With Clear Creek Bio, his goal is to connect the right patient with the right treatment at the right dose.